rs11705701 — IGF2BP2 IGF2BP2 Insulin Signaling Variant

Upstream regulatory variant in IGF2BP2 that shifts mRNA isoform balance in adipose tissue and pancreatic islets, impairing insulin secretion and increasing insulin resistance risk, with moderate evidence for type 2 diabetes susceptibility

See your personal result for IGF2BP2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IGF2BP2: When Your Pancreas Reads the Wrong mRNA

IGF2BP2 is an mRNA-binding protein with an unusual job: it acts as a post-transcriptional regulator of insulin-like growth factor 2 (IGF2), a signaling molecule critical for pancreatic development, beta cell survival, and adipose tissue metabolism. The rs11705701 variant sits about 2 kilobases upstream of the gene and subtly rewires how IGF2BP2 protein is produced — not eliminating it, but shifting which version of the protein dominates in key metabolic tissues.

The Mechanism

The IGF2BP2 gene produces two major protein isoforms: p66 (the full-length form with both RNA-binding domains intact) and p58 (a shorter isoform lacking the N-terminal RRM1 domain). These isoforms are not functionally equivalent. The p58 isoform appears to act as a post-transcriptional brake11 post-transcriptional brake
A regulatory mechanism that modulates how much IGF2 protein is produced from existing mRNA transcript, helping to tune IGF2 output at the tissue level.

The A allele at rs11705701 shifts this balance: research in visceral adipose tissue22 research in visceral adipose tissue
Grishina et al. IGF2BP2 mRNA and protein levels in adipose tissue. Review of Diabetic Studies, 2013 shows that AA homozygotes have reduced p58 and elevated p66 levels. Because p58 lacks the first RNA-recognition motif, reduced p58 availability may disinhibit IGF2 mRNA translation, dysregulating the IGF2 signaling axis in adipose tissue.

IGF2BP2 also functions as an m6A reader33 m6A reader
A protein that recognizes and binds to N6-methyladenosine modifications on mRNA, a major form of epitranscriptomic regulation — it directly binds PDX1 mRNA (a master transcription factor for beta cell identity) and stimulates its translation. Pancreatic beta-cell-specific knockout studies44 Pancreatic beta-cell-specific knockout studies
PMC8076713 — IMP2 deletion reduces compensatory beta cell proliferation by 70% and impairs glucose-stimulated insulin secretion show that loss of IGF2BP2 function dramatically impairs beta cell proliferation and insulin secretion, establishing the gene's critical role in islet homeostasis.

The Evidence

The clearest functional evidence comes from a Russian case-control study (n=2,917)55 Russian case-control study (n=2,917)
Grishina et al. Review of Diabetic Studies, 2013 in which the A allele was associated with T2D risk (OR=1.19, p<0.001). In non-diabetic AA homozygotes, the metabolic phenotype was already visible: higher HOMA-IR (p=0.04), lower HOMA-β (p=0.012), and reduced two-hour insulin levels (p=0.016) — hallmarks of combined insulin resistance and early secretory insufficiency.

Evidence is not uniformly positive. A Chinese prediabetes study (n=1,536) found an association only in females under a dominant model, and a 2024 gestational diabetes study (n=1,703) found no significant association66 found no significant association
Zheng et al. PLoS One, 2024 for rs11705701 specifically. The variant may be a proxy marker for a nearby causal variant rather than functional itself, and population-specific LD patterns explain some of the heterogeneity across ethnicities.

Overall, the evidence supports a moderate classification: replicated signal in multiple populations and datasets, plausible mechanistic basis, but inconsistent across ethnicities and short of clinical-grade evidence.

Practical Implications

Monitoring fasting insulin and two-hour post-load glucose provides earlier warning than HbA1c alone for this genotype.

Interactions

The most clinically important interaction for this variant is with TCF7L2 rs7903146, the strongest single T2D GWAS signal. Both IGF2BP2 and TCF7L2 act in beta cell regulatory circuits — TCF7L2 through Wnt signaling and IGF2BP2 through IGF2/PDX1 axis. Carriers of risk alleles at both loci may carry compounded beta cell dysfunction, warranting especially proactive insulin secretory reserve monitoring.

rs11705701 is in partial but not complete linkage disequilibrium with rs4402960, the originally reported IGF2BP2 GWAS hit from the first wave of T2D genome-wide studies.

Genotype Interpretations

What each possible genotype means for this variant.

GG Typical IGF2BP2 Isoform Balance Normal

No rs11705701 risk alleles — standard IGF2BP2 isoform expression

You carry two copies of the G allele at rs11705701. This is the reference genotype, present in about 28% of people globally. At this locus, your IGF2BP2 gene produces the normal ratio of p66 and p58 isoforms in adipose and islet tissue, supporting standard IGF2 pathway regulation and beta cell function.

Your insulin secretory reserve and insulin sensitivity are not specifically compromised by this IGF2BP2 variant.

AG Intermediate Isoform Shift Intermediate

One A allele — partial shift in IGF2BP2 isoform balance

The intermediate genotype at rs11705701 represents the population majority. The A allele's effect on IGF2BP2 isoform distribution is semi-dominant — even one copy measurably shifts the p58/p66 balance in visceral adipose tissue. Non-diabetic heterozygotes show a trend toward lower insulin response on two-hour OGTT, though not reaching the significant threshold seen in AA homozygotes.

AA Full Isoform Shift High Risk

Two A alleles — maximal IGF2BP2 isoform shift toward p66

The AA genotype at rs11705701 represents the maximum expression of this variant's metabolic effect. The shift from p58 to p66 dominance in adipose tissue appears to dysregulate IGF2 mRNA translation, reducing the post-transcriptional control that p58 provides.

The OR of 1.19 per allele in the Russian cohort translates to roughly 1.42 for AA versus GG homozygotes (1.19²), consistent with typical T2D susceptibility loci. This is a meaningful increment when combined with other metabolic risk factors, not a deterministic sentence.